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Background: The Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) was a prospective, randomized trial comparing two fixed 
doses of dabigatran (D) - 110 mg BID (D110) and 150 mg BID (D150), with open-label warfarin (W) in patients with non-valvular atrial fibrillation 
(AF) with at least one risk factor for stroke. D was non-inferior (D110, relative risk 0.91, p<0.001) and superior (D150, relative risk 0.66, p<0.001) 
to W in reducing the risk of stroke in AF. Orally active direct thrombin inhibitors have not been studied in the setting of cardioversion for AF. The aim 
of this substudy was to analyze 30-day postcardioversion stroke rates for D compared to W.
Methods: Cardioverted patients during the 3-year study period and 30-day postcardioversion stroke rates were analyzed. Exclusion of left atrial 
appendage thrombus with pre-cardioversion transesophageal echocardiography (TEE) was encouraged in those patients assigned to D, but not 
mandated.
Results: A total of 1257 cardioversions were performed during the trial; 411(6.83%), 415 (6.83%) and 431 (7.16%) in the D110, D 150 and W 
group respectively. TEE prior to cardioversion was performed in 144 (35%), 135 (33%) and 76 (18%) of patients in the D110, D150 and W group 
respectively, of which, 1 (0.7%), 2 (1.5%), 1 (1.3%) were positive for thrombus. Patients treated continuously with study drug for ≥ 3 weeks prior 
to cardioversion were similar in all groups: 79, 82 and 87% respectively. Patients discharged in normal sinus rhythm following cardioversion were 
similar: 90% in all groups. Rates of stroke within 30 days of cardioversion were low: 4 (0.03) for D110, 2 (0.02) for D150 and 4 (0.03/100 patient 
years) for W; (D110 vs. W p=0.99, D150 vs. W p=0.42). The event rate was not different in patients with TEE and without TEE prior to cardioversion: 1 
and 3 (0.01 and 0.03/ 100 patient years) for D110 and W, 0 and 2 (0.0 and 0.02/ 100 patient years) for D150.
Conclusions: In this first evaluation of dabigatran in patients cardioverted for AF, stroke rates were low in dabigatran as well as in warfarin treated 
patients, with and without TEE guidance. Dabigatran may be a safe alternative to warfarin for stroke prevention at cardioversion.
